@article{kumar_true_2025,
	title = {A true theranostic pair – 44/47Sc-labeled {GRPR} antagonist shows great promise for managing prostate and breast cancer},
	issn = {1619-7089},
	url = {https://doi.org/10.1007/s00259-025-07651-y},
	doi = {10.1007/s00259-025-07651-y},
	abstract = {This study investigates the theranostic potential of a 44/47Sc-labeled antagonist targeting the gastrin-releasing peptide receptor ({GRPR}) in prostate and breast tumors.},
	journaltitle = {European Journal of Nuclear Medicine and Molecular Imaging},
	shortjournal = {Eur J Nucl Med Mol Imaging},
	eprinttype = {pubmed},
	eprint = {https://pubmed.ncbi.nlm.nih.gov/41217470/},
	author = {Kumar, Naveen and Bilinska, Adrianna and Menéndez, Elena and Läppchen, Tilman and Moon, Euy Sung and Zoltowska, Malgorzata and Pawlak, Dariusz and Cieszykowska, Izabela and Mikolajczak, Renata and Rösch, Frank and Rominger, Axel and Gourni, Eleni},
	urldate = {2025-11-12},
	date = {2025-11-11},
	langid = {english},
	keywords = {44/47Sc, Everolimus, Fractionated dose, {GRPR} antagonist, {mTOR} inhibitor, user-project},
}